Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

24/07/2026 14:10

Kiniksa Pharmaceuticals International, PLC KNSA.OQ KNSA.O is expected to  show a rise in quarterly revenue when it reports  results on July 28 for the period ending June 30 2026
The London England-based  company is expected to report a 43.8% increase in revenue to $225.457 million from $156.8 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals International, PLC is for earnings of 30 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $72.00, about 14.2% above its last closing price of $63.05
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.21
0.20
0.27
Beat
34.2
Dec. 31 2026
0.35
0.37
0.17
Missed
-54.6
Sep. 30 2025
0.32
0.32
0.23
Missed
-28.9​
Jun. 30 2025
0.17
0.18
0.23
Beat
26.3
​​Mar. 31 2025
-0.01
0.04
0.11
Beat
161.9
Dec. 31 2024
-0.10
0.00
-0.12
Missed
-5,900​
Sep. 30 2024
-0.02
0.03
-0.18
Missed
-662.5
Jun. 30 2024
-0.07
-0.07
-0.06
Beat
20
This summary was machine generated July 24 at 13:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)